- Home
- NUS vs CADL Comparison
NUS vs CADL Comparison
Compare NUS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUS
- CADL
- Stock Information
- Founded
- NUS 1984
- CADL 1999
- Country
- NUS United States
- CADL United States
- Employees
- NUS N/A
- CADL N/A
- Industry
- NUS Other Pharmaceuticals
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- NUS Health Care
- CADL Health Care
- Exchange
- NUS Nasdaq
- CADL Nasdaq
- Market Cap
- NUS 308.1M
- CADL 234.8M
- IPO Year
- NUS 1996
- CADL 2021
- Fundamental
- Price
- NUS $6.15
- CADL $4.76
- Analyst Decision
- NUS Hold
- CADL Strong Buy
- Analyst Count
- NUS 2
- CADL 4
- Target Price
- NUS $6.88
- CADL $21.00
- AVG Volume (30 Days)
- NUS 626.1K
- CADL 864.6K
- Earning Date
- NUS 05-08-2025
- CADL 05-13-2025
- Dividend Yield
- NUS 3.90%
- CADL N/A
- EPS Growth
- NUS N/A
- CADL N/A
- EPS
- NUS N/A
- CADL N/A
- Revenue
- NUS $1,732,084,000.00
- CADL N/A
- Revenue This Year
- NUS N/A
- CADL N/A
- Revenue Next Year
- NUS N/A
- CADL N/A
- P/E Ratio
- NUS N/A
- CADL N/A
- Revenue Growth
- NUS N/A
- CADL N/A
- 52 Week Low
- NUS $5.32
- CADL $3.79
- 52 Week High
- NUS $14.00
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- NUS 49.12
- CADL 41.42
- Support Level
- NUS $5.63
- CADL $4.80
- Resistance Level
- NUS $6.36
- CADL $5.34
- Average True Range (ATR)
- NUS 0.27
- CADL 0.33
- MACD
- NUS 0.08
- CADL 0.10
- Stochastic Oscillator
- NUS 79.81
- CADL 42.09
About NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.